ArticleBiology direct2026
Mechanistic insights into TXNDC17-mediated ferroptosis suppression in glioblastoma progression.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) is a lethal brain tumor with limited treatment options. Molecular targeted therapy is considered safe and promising for GBM. Ferroptosis is regulated by lipid, iron and cysteine metabolism. Induction of ferroptosis is a promising strategy.
methodsIntegrated bioinformatics analysis of GBM datasets (TCGA) and RNA-seq data from human gliomas was used to identify candidate genes. TXNDC17 expression was validated in glioma tissues and cell lines by qPCR, western blotting and immunofluorescence. In vitro functional assays (CCK-8, wound healing, Transwell) were performed to assess proliferation, migration and invasion following TXNDC17 knockdown (siRNA). Ferroptosis sensitivity was evaluated by measuring GSH and LPO levels after TXNDC17 manipulation. GPX4 rescue experiments were conducted. In vivo therapeutic efficacy was examined in orthotopic GBM mouse models using TXNDC17-silenced cells treated with RSL3 (an inhibitor of GPX4) with tumor growth monitored by bioluminescence.
resultsBioinformatics analysis identified TXNDC17 as a key prognostic risk factor. Molecular validation confirmed grade-dependent TXNDC17 overexpression in gliomas. TXNDC17 knockdown markedly suppressed GBM cell proliferation, migration and invasion. Mechanistically, TXNDC17 promoted glioma progression by regulating ferroptosis, specifically through cooperation with GPX4 to inhibit ferroptosis. Knockdown reduced GPX4 expression, thereby increasing ferroptosis sensitivity. GPX4 overexpression rescued proliferation and invasion defects caused by TXNDC17 knockdown, confirming its functional dependence. TXNDC17 silencing combined with RSL3 synergistically suppressed GBM growth in vitro.
conclusionTXNDC17 functions as a novel oncoprotein and ferroptosis suppressor in GBM by regulating GPX4 and promoting tumor progression. Targeting the TXNDC17-GPX4 axis through TXNDC17 silencing and RSL3 treatment represents a potent synergistic therapeutic strategy.
Indexed as
Identifiers
42449447What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.